Wilson Troy Edward Sells 10,800 Shares of PBYI

On June 12, 2026, Wilson Troy Edward sold 10,800 shares of PBYI in a planned transaction. The shares were sold at an average price of $7.20, bringing the total value of the sale to $77,760. This sale was disclosed as part of a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks.

Insider Buying and Selling at Puma Biotechnology, Inc.

Recent insider activity at PBYI on June 12, 2026, included several planned sales. Allison Dorval sold 11,610 shares, Brian Stuglik sold 8,100 shares, and Adrian Senderowicz sold 27,000 shares, all at an average price of $7.20. On the same date, Jay Moyes sold 22,000 shares at $7.22. Notably, on June 11, 2026, Jay Moyes also bought 27,000 shares in a non-planned transaction.

Other Institutional Activity in PBYI

Institutional investors have been adjusting their positions in PBYI. ACORN Capital Advisors, LLC maintained its stake with 4,131,299 shares valued at approximately $26.4 million. BlackRock, Inc. reduced its holdings by 43,636 shares, ending with 3,598,952 shares worth about $22.9 million. Acadian Asset Management LLC increased its position by 16,936 shares to hold 2,041,759 shares valued at $13 million. Renaissance Technologies LLC cut its stake by 181,400 shares, resulting in 1,942,413 shares worth $12.4 million. Meanwhile, American Century Companies Inc. boosted its holdings by 266,209 shares, reaching 1,916,346 shares valued at $12.2 million.

Puma Biotechnology, Inc. Stock Down 19.1%

Shares of PBYI are trading near $7.33. The stock has attracted various institutional investors, and recent insider transactions have been disclosed. PBYI is closely watched by analysts and investors alike, with recent ratings reflecting diverse opinions on its future performance.

Analysts Set New Price Targets

On February 28, 2025, HC Wainwright & Co. reiterated its 'buy' rating for PBYI, setting a price target of $7.00. This reflects continued optimism from the firm about PBYI's prospects. Analyst consensus shows a mixed outlook, with some firms maintaining 'hold' or 'sell' ratings, indicating varied expectations for the stock's future.

Bottom Line

Wilson Troy Edward's recent sale of PBYI shares is part of a planned transaction, highlighting insider activity at the company. Institutional investors have been adjusting their stakes, with some increasing and others reducing their holdings. Analysts offer mixed ratings, providing a range of perspectives on the company's potential. As always, 13F filings and insider transactions are backward-looking and may not represent current positions.